Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RLS-01 (Revixia Life Sciences)
- Development stage
- Unknown
- Lead developer
- Eli Lilly
- Modality
- Small Molecules
- Administration
- Transmucosal
01
Overview
RLS-01 is a small molecule therapeutic being developed by Revixia Life Sciences, a subsidiary of atai Life Sciences, for the treatment of treatment-resistant depression (TRD). It is a proprietary formulation of salvinorin A, a potent and highly selective kappa-opioid receptor (KOR) agonist derived from the plant *Salvia divinorum*. Unlike classic psychedelics that primarily target the serotonin 5-HT2A receptor, RLS-01 exerts its effects through the opioid system, offering a distinct pharmacological approach to rapid-acting antidepressant therapy. The drug is designed as a transmucosal formulation to optimize delivery and provide a controlled, short-duration psychedelic experience with a rapid onset, potentially allowing for convenient administration within a clinical setting.
- Other names
- salvinorin A
02
Targets
KOR (Kappa opioid receptor)
Beyond the preview
Go deeper on RLS-01 (Revixia Life Sciences).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RLS-01 (Revixia Life Sciences).